Technical Analysis for CLSD - Clearside Biomedical, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 0.00% | |
| Crossed Above 20 DMA | Bullish | 0.00% | |
| Bollinger Band Squeeze | Range Contraction | 0.00% | |
| Bollinger Band Squeeze | Range Contraction | 3.13% | |
| Bollinger Band Squeeze | Range Contraction | 7.32% | |
| NR7 | Range Contraction | 7.32% | |
| Narrow Range Bar | Range Contraction | 7.32% | |
| Fell Below 20 DMA | Bearish | 5.60% | |
| Bollinger Band Squeeze | Range Contraction | 5.60% | |
| Earnings Movers | Other | 5.60% |
| Alert | Time |
|---|---|
| 20 DMA Resistance | about 21 hours ago |
| Rose Above Previous Day's High | about 21 hours ago |
| Up 3% | about 21 hours ago |
| Up 2% | about 21 hours ago |
| Up 1% | about 21 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/09/2024
Clearside BioMedical, Inc., a biopharmaceutical company, develops drug therapies to treat chronic blinding diseases of the eye. Its products include CLS-1001 for the treatment of macular edema associated with non-infectious uveitis; CLS-1003 for the treatment of macular edema associated with retinal vein occlusion; and CLS-1002 program for the treatment of wet age-related macular degeneration. The company was founded in 2011 and is headquartered in Alpharetta, Georgia.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Eye Ophthalmology Macular Degeneration Macular Edema Retina Veins Wet Age Related Macular Degeneration Drug Therapies Uveitis Adverum Biotechnologies Non Infectious Uveitis Retinal Vein Occlusion
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Eye Ophthalmology Macular Degeneration Macular Edema Retina Veins Wet Age Related Macular Degeneration Drug Therapies Uveitis Adverum Biotechnologies Non Infectious Uveitis Retinal Vein Occlusion
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 2.12 |
| 52 Week Low | 0.6501 |
| Average Volume | 432,654 |
| 200-Day Moving Average | 1.15 |
| 50-Day Moving Average | 1.43 |
| 20-Day Moving Average | 1.30 |
| 10-Day Moving Average | 1.29 |
| Average True Range | 0.11 |
| RSI (14) | 50.00 |
| ADX | 14.56 |
| +DI | 14.70 |
| -DI | 12.09 |
| Chandelier Exit (Long, 3 ATRs) | 1.15 |
| Chandelier Exit (Short, 3 ATRs) | 1.43 |
| Upper Bollinger Bands | 1.39 |
| Lower Bollinger Band | 1.22 |
| Percent B (%b) | 0.6 |
| BandWidth | 13.31 |
| MACD Line | -0.03 |
| MACD Signal Line | -0.03 |
| MACD Histogram | 0.0073 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.43 | ||||
| Resistance 3 (R3) | 1.42 | 1.37 | 1.41 | ||
| Resistance 2 (R2) | 1.37 | 1.35 | 1.38 | 1.40 | |
| Resistance 1 (R1) | 1.35 | 1.33 | 1.36 | 1.36 | 1.40 |
| Pivot Point | 1.30 | 1.30 | 1.31 | 1.31 | 1.30 |
| Support 1 (S1) | 1.28 | 1.28 | 1.29 | 1.29 | 1.24 |
| Support 2 (S2) | 1.23 | 1.26 | 1.24 | 1.24 | |
| Support 3 (S3) | 1.21 | 1.23 | 1.23 | ||
| Support 4 (S4) | 1.22 |
